Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 10, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references an employee stock purchase plan
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001699488-26-000002
Filed / recorded
Feb 12, 2026, 9:30 PM UTC
Added to OQRO
Oct 6, 2026, 10:35 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
COLLEGIUM PHARMACEUTICAL, INC
Issuer CIK
1267565
Ticker
COLL
Reporting person
Vikram Karnani
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 10, 2026
Transaction code
A
Shares / units
79,264
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
176,629
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan.